- Home
- ALIT vs ICUI Comparison
ALIT vs ICUI Comparison
Compare ALIT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALIT
- ICUI
- Stock Information
- Founded
- ALIT 2017
- ICUI 1984
- Country
- ALIT United States
- ICUI United States
- Employees
- ALIT N/A
- ICUI N/A
- Industry
- ALIT Business Services
- ICUI Medical/Dental Instruments
- Sector
- ALIT Consumer Discretionary
- ICUI Health Care
- Exchange
- ALIT Nasdaq
- ICUI Nasdaq
- Market Cap
- ALIT 3.5B
- ICUI 3.8B
- IPO Year
- ALIT N/A
- ICUI 1992
- Fundamental
- Price
- ALIT $6.82
- ICUI $157.26
- Analyst Decision
- ALIT Strong Buy
- ICUI Buy
- Analyst Count
- ALIT 9
- ICUI 4
- Target Price
- ALIT $10.61
- ICUI $199.67
- AVG Volume (30 Days)
- ALIT 6.6M
- ICUI 190.0K
- Earning Date
- ALIT 02-20-2025
- ICUI 02-27-2025
- Dividend Yield
- ALIT 1.17%
- ICUI N/A
- EPS Growth
- ALIT N/A
- ICUI N/A
- EPS
- ALIT N/A
- ICUI N/A
- Revenue
- ALIT $2,332,000,000.00
- ICUI $2,340,097,000.00
- Revenue This Year
- ALIT $4.80
- ICUI $4.38
- Revenue Next Year
- ALIT $4.09
- ICUI $0.34
- P/E Ratio
- ALIT N/A
- ICUI N/A
- Revenue Growth
- ALIT N/A
- ICUI 4.04
- 52 Week Low
- ALIT $6.15
- ICUI $93.36
- 52 Week High
- ALIT $10.38
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- ALIT 51.15
- ICUI 42.90
- Support Level
- ALIT $6.52
- ICUI $155.25
- Resistance Level
- ALIT $7.66
- ICUI $165.17
- Average True Range (ATR)
- ALIT 0.24
- ICUI 4.73
- MACD
- ALIT 0.03
- ICUI -0.09
- Stochastic Oscillator
- ALIT 31.43
- ICUI 19.81
About ALIT Alight Inc.
Alight Inc is a provider of integrated, cloud-based human capital solutions that empower clients and employees to manage health, wealth and HR needs. Geographically, the company generates a majority of its revenue from the United States.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.